Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Non-Small Cell Lung Cancer × Gemcitabine × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 66 Carcinoma, Non-Small-Cell Lung 56 Breast Neoplasms 31 Lung Neoplasms 26 Nasopharyngeal Carcinoma 25 Urinary Bladder Neoplasms 22 Ovarian Neoplasms 17 Neoplasm Metastasis 17 Cholangiocarcinoma 14 Uterine Cervical Neoplasms 12 Lymphoma, Large B-Cell, Diffuse 12 Gallbladder Neoplasms 12 Biliary Tract Neoplasms 12 Triple Negative Breast Neoplasms 11 Recurrence 11 Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Carcinoma, Transitional Cell 10 Non-Muscle Invasive Bladder Neoplasms 9 Nasopharyngeal Neoplasms 7 Fallopian Tube Neoplasms 7 Carcinoma 7 Bile Duct Neoplasms 7 Lymphoma, Non-Hodgkin 6 Lymphoma 6 Adenocarcinoma 5 Carcinoma, Hepatocellular 4 Urothelial Cancer 3 Neoplasms by Site 3 Lymphoma, T-Cell, Peripheral 3

Interventions

pembrolizumab 1 Vinorelbine 1 Gemcitabine 1 Docetaxel 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00345059 2016-01-14

DISTAL-2

National Cancer Institute, Naples

Phase 3 Terminated

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡